NovaBridge Biosciences
NASDAQ:NBPBiotechnology
-$0.07 today
- Market cap
- $104.10M
- Beta
- 1.48
- P/E (TTM)
- -25.5
- EPS (TTM)
- -$0.40
Volume 0.87M
Average 0.90M
NBP EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
NovaBridge BiosciencesNASDAQ: NBP
EBITDA · Q4 FY2025 · quarter ended Dec 2025
EBITDA remains negative
Q4 FY2025 EBITDA was -$10.39M, compared with -$12.1M a year earlier. Trailing-twelve-month EBITDA was -$33.25M.
Context
- EBITDA grew in size in 2 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the +96.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterDec 2025
- -$10.39M-18.4% QoQ
- Last fiscal yearDec 2025
- -$13.35M+96.4% YoY
- LTMSep 2025
- -$33.25M+92.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +14.1% | +100.0% | +85.9 pp |
| 1 year | +96.4% | +100.0% | +3.6 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
Mixed currencies · from the income statement
- Latest · FY2025
- (13.35M) USD
- Year-over-year change
- —
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (13.35M) | — |
| FY2024 | 2024-12-31 | (373.45M) | -8.5% |
| FY2023 | 2023-12-31 | (344.25M) | -572.0% |
| FY2022 | 2022-12-31 | (51.23M) | +97.5% |
| FY2021 | 2021-12-31 | (2.06B) | — |
EBITDA vs competitors
How NBP compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +92.9% is the highest of 10, against a peer median of -19.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$18.62M USD | +52.1% | — | — | |
NBPNovaBridge Biosciences | LTM Sep 2025 | -CN¥33.25M CNY | +92.9% | — | — |
| LTM Mar 2026 | -$35.03M USD | -30.1% | — | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | -$39.05M USD | — | — | — |
| LTM Mar 2026 | -$44.93M USD | -42.6% | — | — | |
| LTM Mar 2026 | -$69.09M USD | -24.3% | — | — | |
| LTM Mar 2026 | -$88.27M USD | +2.7% | — | 245200.0% | |
| LTM Mar 2026 | -$111.17M USD | -19.0% | — | — | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | -$125.94M USD | -65.1% | — | — |
| LTM Mar 2026 | -$193.41M USD | -17.1% | — | — | |
| LTM Mar 2026 | -$194.47M USD | +21.0% | — | — | |
| Peer median (excluding NBP) | — | -19.0% | — | 245200.0% | |
Competitors are the stored peer set for NBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 · CNY | FY2022 Dec 2022 · CNY | FY2023 Dec 2023 · CNY | FY2024 Dec 2024 · CNY | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Revenue | 88.03M | (10.7M) | 4.49M | 0 | 0 |
| Cost of Revenue | 46.43M | 0 | 0 | 0 | 0 |
| Gross Profit | 41.59M | (10.7M) | 4.49M | 0 | 0 |
| Gross Margin | 47.3% | 100.0% | 100.0% | — | — |
| Research & Development | 190.29M | 155.51M | 114.36M | 158.9M | 8.99M |
| Selling, General & Admin | 899.94M | 199.88M | 63.91M | 216.46M | 4.48M |
| Operating Expenses | 2.11B | 355.38M | 515.65M | 375.36M | 13.48M |
| Depreciation & Amortization | 13.78M | 1.42M | 3.37M | 1.91M | 122.37K |
| EBITDA | (2.06B) | (51.23M) | (344.25M) | (373.45M) | (13.35M) |
| EBITDA Margin | -2337.4% | 478.9% | -7674.2% | — | — |
| Operating Income | (2.07B) | (366.08M) | (511.16M) | (375.36M) | (13.48M) |
| Operating Margin | -2353.1% | 3422.2% | -11395.1% | — | — |
| Interest Income | 21.33M | 4.95M | 7.3M | 54.64M | 1.09M |
| Interest Expense | 0 | 0 | 101.85K | 0 | 0 |
| Other Income / Expenses | (260.73M) | (607.09M) | (954.53M) | 12.63M | 847.61K |
| Income Before Tax | (2.33B) | (973.17M) | (1.47B) | (362.73M) | (12.63M) |
| Pre-Tax Margin | -2649.3% | 9097.4% | -32674.0% | — | — |
| Income Tax Expense | (494.81K) | 710.39K | (1.26B) | 0 | 0 |
| Net Income | (2.33B) | (2.51B) | (1.47B) | (162.26M) | (6.61M) |
| Net Margin | -2648.7% | 23438.9% | -32674.0% | — | — |
| EPS (Basic) | (30.70) | (30.38) | (17.62) | (4.46) | (0.16) |
| EPS (Diluted) | (30.68) | (30.38) | (17.62) | (4.46) | (0.16) |
| Weighted Avg Shares | 75.93M | 82.52M | 83.19M | 81.19M | 41.64M |
| Weighted Avg Shares (Diluted) | 75.96M | 82.52M | 83.23M | 81.19M | 41.64M |
NovaBridge Biosciences
NASDAQ:NBP
Intrinsic Alpha fair value
Locked
Current Price
$0.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.